Lyrica is a Schedule V controlled substance
Executive Summary
Pfizer plans to launch Lyrica (pregabalin) in the fall following DEA's July 28 final rule classifying the drug as a Schedule V controlled substance. Launch of the gabapentin follow-on has been delayed by the scheduling process. FDA cleared pregabalin in December for neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia; Lyrica added an indication for partial onset seizures in June (1"The Pink Sheet" June 20, 2005, In Brief)...